Literature DB >> 29493484

The effect of concomitant use of systemic antibiotics in patients with Clostridium difficile infection receiving metronidazole therapy.

S J Jin1, K H Seo1, Y M Wi1,2.   

Abstract

Management of Clostridium difficile infection (CDI) involves discontinuation of the offending antibiotic agent as soon as possible. However, the ongoing infection does not allow discontinuation of the offending antibiotic. We aimed to retrospectively investigate the predictors of treatment failure and impact of the concomitant use of systemic antibiotics in patients receiving metronidazole therapy. This study was conducted among patients hospitalised at a second care academic hospital from January 2013 to December 2014. Eligible patients were identified by reviewing stool toxin enzyme immunoassay results for C. difficile. Diarrhoea was defined as the passage of at least three loose or watery stools within 24 h. Among 314 patients with CDI receiving metronidazole therapy, 62 (19.7%) showed treatment failure and 105 (33.4%) received concomitant antibiotics. Underlying dialysis, fever >38.3 °C, low median serum albumin levels and concomitant use of antibiotics were independent predictors of treatment failure in patients with CDI receiving metronidazole therapy. The concomitant use of antibiotics increased the rates of treatment failure and 30-day mortality in patients receiving metronidazole therapy. These results suggest that metronidazole should be used in mild cases of CDI only after discontinuation of the offending antibiotics.

Entities:  

Keywords:  zzm321990 Clostridium difficile infection; concomitant antibiotics; metronidazole; treatment failure

Mesh:

Substances:

Year:  2018        PMID: 29493484      PMCID: PMC9134508          DOI: 10.1017/S0950268818000390

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  29 in total

1.  Antimicrobial use and risk for recurrent Clostridium difficile infection.

Authors:  Dimitri M Drekonja; William H Amundson; Douglas D Decarolis; Michael A Kuskowski; Frank A Lederle; James R Johnson
Journal:  Am J Med       Date:  2011-09-22       Impact factor: 4.965

2.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

3.  Clindamycin-associated colitis. A prospective study.

Authors:  F J Tedesco; R W Barton; D H Alpers
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Effect of treatment variation on outcomes in patients with Clostridium difficile.

Authors:  Adam T Brown; Charles F Seifert
Journal:  Am J Med       Date:  2014-05-23       Impact factor: 4.965

Review 5.  Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  C Thongprayoon; W Cheungpasitporn; P Phatharacharukul; P J Edmonds; Q Kaewpoowat; P Mahaparn; J Bruminhent; S B Erickson
Journal:  Int J Clin Pract       Date:  2015-07-05       Impact factor: 2.503

6.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

7.  Factors associated with failure of metronidazole in Clostridium difficile-associated disease.

Authors:  Angel Fernandez; Girish Anand; Frank Friedenberg
Journal:  J Clin Gastroenterol       Date:  2004 May-Jun       Impact factor: 3.062

8.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

9.  Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.

Authors:  Martijn P Bauer; Marjolein P M Hensgens; Mark A Miller; Dale N Gerding; Mark H Wilcox; Adam P Dale; Warren N Fawley; Ed J Kuijper; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

Review 10.  A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.

Authors:  Hannah E Burton; Stephen A Mitchell; Maureen Watt
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

View more
  2 in total

1.  Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea.

Authors:  Jaeuk Shin; Yu Mi Wi; Yu-Ji Lee
Journal:  Epidemiol Infect       Date:  2019-10-14       Impact factor: 2.451

2.  Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.

Authors:  Gregory R Madden; William A Petri; Deiziane V S Costa; Cirle A Warren; Jennie Z Ma; Costi D Sifri
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.